Stock data
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT) reported net income of -US$59.00M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | — | -US$59.00M | — |
| 2024 | — | — | — | -US$70.78M | — |
| 2023 | — | — | — | -US$63.67M | — |
| 2022 | — | — | — | -US$57.92M | — |
| 2021 | — | — | — | -US$50.31M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.19M | -US$14.47M | — |
| 2026-03-31 | — | -US$14.70M | — |
| 2025-12-31 | — | -US$13.78M | — |
| 2025-09-30 | — | -US$13.57M | — |
| 2025-06-30 | US$0.00M | -US$15.03M | — |
| 2025-03-31 | — | -US$16.61M | — |
| 2024-12-31 | — | -US$17.59M | — |
| 2024-09-30 | — | -US$16.45M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.